
In this episode of Petri Dish Perspectives, we explore Jiangsu Hengrui Pharmaceuticals, the Chinese pharma giant that started as a state-owned generic drug factory in 1970 and quietly became one of the most important drug companies in the world. Over $15 billion in deals with GSK and Novo Nordisk. The world's top clinical trial sponsor. One of the top five drug pipelines globally. All from a city most people can't find on a map.
We break down how Hengrui made the pivot from generics to innovation, why Western pharma is now writing billion-dollar checks for Chinese science, and the controversies, including a scathing FDA warning letter and corruption scandals, that complicate the story.
Because Hengrui wasn't hiding. It was building, the whole time.
š§ Listen now, stay curious, and donāt forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #Hengrui #ChinaBiotech #Pharma #Biotech #DrugDiscovery #NovoNordisk #GSK #GLP1 #Oncology #LifeSciences #Healthcare #BiotechInnovation #PharmaceuticalIndustry
Ā© 2026 The Perspective Bureau LLC. All rights reserved.
More episodes from "PETRI DISH PERSPECTIVES"



Don't miss an episode of āPETRI DISH PERSPECTIVESā and subscribe to it in the GetPodcast app.








